Back to Search
Start Over
Further evidence for a functional role of the glutamate receptor gene GRM3 in schizophrenia
- Source :
-
European Neuropsychopharmacology . Oct2008, Vol. 18 Issue 10, p768-772. 5p. - Publication Year :
- 2008
-
Abstract
- Abstract: In recent years, evidence has been accumulating indicating a major role of glutamate in the pathogenesis and pathophysiology of schizophrenia. Of particular importance in this regard are the metabotropic glutamate receptors (GRM). Thus, a recently published trial of the amino acid analogue LY2140023, which exerts its effects through the activation of the glutamate receptors GRM3/GRM2, showed an improvement of positive and negative symptoms comparable to treatment with olanzapine. A functional variant of GRM3 has been described which modulates synaptic glutamate levels. We assessed whether this functional variant rs6465084 is related to schizophrenia in a large sample of patients and controls. We found an increased frequency of the A allele (p =0.027) and the AA genotype (p =0.024) in schizophrenia patients. Moreover, in an assessment of schizophrenia endophenotypes, patients of the AA genotype performed poorly in the digit symbol test, a measure of attention (p =0.008). Our results provide further evidence for the potential importance of the glutamate receptor GRM3 in schizophrenia, and indicate that the novel antipsychotic LY2140023 may actually be targeting a pathogenic pathway of schizophrenia. [Copyright &y& Elsevier]
- Subjects :
- *SCHIZOPHRENIA
*GLUTAMIC acid
*AMINO acids
*OLANZAPINE
Subjects
Details
- Language :
- English
- ISSN :
- 0924977X
- Volume :
- 18
- Issue :
- 10
- Database :
- Academic Search Index
- Journal :
- European Neuropsychopharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 33993751
- Full Text :
- https://doi.org/10.1016/j.euroneuro.2008.05.007